A PENNdemic Year in Review

  • Sarah E. Herlihy
    Correspondence
    Corresponding author.
    Affiliations
    Department of Pathology and Laboratory Medicine, Molecular Pathology Laboratory, Hospital of the University of Pennsylvania, 7 Maloney Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Caren Gentile
    Affiliations
    Department of Pathology and Laboratory Medicine, Molecular Pathology Laboratory, Hospital of the University of Pennsylvania, 7 Maloney Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
Published:September 01, 2021DOI:https://doi.org/10.1016/j.yamp.2021.06.007
      A dedicated clinical development team is advantageous and allows flexibility during an emergency so that clinical work can continue uninterrupted.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dong E.
        • Du H.
        • Gardner L.
        An interactive web-based dashboard to track COVID-19 in real time.
        Lancet Infect Dis. 2020; 20: 533-534
      1. COVID-19 in Pennsylvania. Pennsylvania Department of Health, 2021 (Available at:) (Accessed April 9, 2021)
      2. Coronavirus disease 2019 (COVID-19): providing information and updates about COVID-19 in Philadelphia. Philadelphia Department of Health, 2021 (Available at:) (Accessed April 9, 2021)
      3. Opening remarks at the media briefing on COVID19 [press release]. 2021 (Available at:)
        • Giorgi G.
        • Lecca L.I.
        • Alessio F.
        • et al.
        COVID-19-related mental health effects in the workplace: a narrative review.
        Int J Environ Res Public Health. 2020; 17: 7857
        • Wu K.L.
        ‘Nobody sees us’: testing-lab workers strain under demand.
        (Available at:) (Accessed April 8, 2021)
      4. Association for Molecular Pathology SARS-CoV-2 molecular testing: summary of August SARS-CoV-2 molecular testing survey. Association for Molecular Pathology, 2020 (Available at:)
      5. Association for Molecular Pathology SARS-CoV-2 Molecular Testing: Summary of April SARS-CoV-2 Molecular Testing Survey. Association for Molecular Pathology;2020.

      6. Gentile C, Richard-Greenblatt, M, Fink, J, et al. A practical comparison of seven molecular SARS-CoV-2 methods paper presented at: Association for Molecular Pathology Annual Meeting November 16-20, 2020.

        • Wrighton M.S.
        • Lawrence S.J.
        Reopening colleges and universities during the COVID-19 pandemic.
        Ann Intern Med. 2020; 173: 664-665
        • Odriozola-Gonzalez P.
        • Planchuelo-Gomez A.
        • Irurtia M.J.
        • et al.
        Psychological effects of the COVID-19 outbreak and lockdown among students and workers of a Spanish university.
        Psychiatry Res. 2020; 290: 113108
        • Dhar B.K.
        • Ayittey F.K.
        • Sarkar S.M.
        Impact of COVID-19 on psychology among the university students.
        Glob Chall. 2020; 4: 2000038
        • Paltiel A.D.
        • Zheng A.
        • Walensky R.P.
        Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States.
        JAMA Netw Open. 2020; 3: e2016818
        • Tanabe K.O.
        • Hayden M.E.
        • Zunder B.
        • et al.
        Identifying vulnerable populations at a university during the COVID-19 pandemic.
        J Am Coll Health. 2021; : 1-4
        • Van Pelt A.
        • Glick H.A.
        • Yang W.
        • et al.
        Evaluation of COVID-19 testing strategies for repopulating college and university campuses: a decision tree analysis.
        J Adolesc Health. 2021; 68: 28-34
      7. Overview of testing for SARS-CoV-2 (COVID-19). Centers for Disease Control and Prevention, 2021 (Available at:) (Accessed March 25, 2021)
      8. Screening for COVID-19: deciding which test to use when establishing testing programs. U.S. Food and Drug Administration, 2021 (Available at:) (Accessed March 25, 2021)
        • Ryan B.J.
        • Muehlenbein M.P.
        • Allen J.
        • et al.
        Sustaining university operations during the COVID-19 pandemic.
        Disaster Med Public Health Prep. 2021; : 1-24
      9. COVID-19 dashboard. University of Pennsylvania, 2021 (Available at:) (Accessed 2021)
      10. West Philadelphia Skills Initiative. 2021 (Available at:) (Accessed April 7, 2021)
        • CDC OneLab
        Division of laboratory systems.
        2021 (Available at:) (Accessed April 7, 2021)
        • Meredith L.W.
        • Hamilton W.L.
        • Warne B.
        • et al.
        Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study.
        Lancet Infect Dis. 2020; 20: 1263-1271
      11. CLIA SARS-CoV-2 variant testing frequently asked question.
        (Available at:) (Accessed April 5, 2021)
        • Harilal D.
        • Ramaswamy S.
        • Loney T.
        • et al.
        SARS-CoV-2 whole genome amplification and sequencing for effective population-based surveillance and control of viral transmission.
        Clin Chem. 2020; 66: 1450-1458
        • Behrmann O.
        • Spiegel M.
        COVID-19: from rapid genome sequencing to fast decisions.
        Lancet Infect Dis. 2020; 20: 1218
      12. Emergency Use Authorization. 2021 (Available at:) (Accessed April 8, 2021)
      13. SARS-CoV-2 viral mutations: impact on COVID-19 tests. 2021 (Available at:) (Accessed June 8, 2021)
        • Artesi M.
        • Bontems S.
        • Gobbels P.
        • et al.
        A recurrent mutation at position 26340 of SARS-CoV-2 is associated with failure of the e gene quantitative reverse transcription-PCR utilized in a commercial dual-target diagnostic assay.
        J Clin Microbiol. 2020; 58: e01598
        • Staff B.T.B.
        Thermo Fisher’s COVID-19 tests: designed with virus mutations in mind. vol. 2021. 2020 (Available at:)
        • Hasan M.R.
        • Sundararaju S.
        • Manickam C.
        • et al.
        A novel point mutation in the N gene of SARS-CoV-2 may affect the detection of the virus by reverse transcription-quantitative PCR.
        J Clin Microbiol. 2021; 59: e03278
      14. FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under Emergency Use Authorization. 2021 (Available at:) (Accessed June 8, 2021)
        • Taylor P.C.
        • Adams A.C.
        • Hufford M.M.
        • et al.
        Neutralizing monoclonal antibodies for treatment of COVID-19.
        Nat Rev Immunol. 2021; 21: 382-393
        • Tada T.
        • Dcosta B.M.
        • Zhou H.
        • et al.
        Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
        bioRxiv. 2021;
        • Volz E.
        • Mishra S.
        • Chand M.
        • et al.
        Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
        Nature. 2021;
        • Callaway E.
        Multitude of coronavirus variants found in the US - but the threat is unclear.
        Nature. 2021; 591: 190
        • Deng X.
        • Garcia-Knight M.A.
        • Khalid M.M.
        • et al.
        Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.
        medRxiv. 2021;
        • Annavajhala M.K.
        • Mohri H.
        • Zucker J.E.
        • et al.
        A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York.
        medRxiv. 2021;
        • Furuse Y.
        Genomic sequencing effort for SARS-CoV-2 by country during the pandemic.
        Int J Infect Dis. 2021; 103: 305-307
        • Domingo E.
        • Perales C.
        The time for COVID-19 vaccination.
        J Virol. 2021;
        • Kennedy D.A.
        • Read A.F.
        Monitor for COVID-19 vaccine resistance evolution during clinical trials.
        PLoS Biol. 2020; 18: e3001000
        • Wadman M.
        United States rushes to fill void in viral sequencing.
        Science. 2021; 371: 657-658
      15. UNC surveillance report. UNC Contributing labs. 2021 (Available at:) (Accessed April 8, 2021)
      16. Genomic surveillance for SARS-CoV-2 variants. National Center for Immunization and Respiratory Diseases (NCIRD), division of viral diseases.
        (Available at:) (Accessed April 8, 2021)